Safety and adherence for 12 weekly doses of isoniazid and rifapentine for pediatric tuberculosis infection

Pediatric Infectious Disease Journal

Volumn 35, Issue 7, 2016, Pages 811-813

  Cruz, Andrea T ^a   Starke, Jeffrey R ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

3HP; adherence; completion rates

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ISONIAZID; RIFAMPICIN; RIFAPENTINE; TUBERCULOSTATIC AGENT;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHILD; COHORT ANALYSIS; DRUG SAFETY; DRUG SENSITIVITY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERTRANSAMINASEMIA; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MULTIPLE CYCLE TREATMENT; NAUSEA; POLYPHARMACY; PRIORITY JOURNAL; RASH; TUBERCULOSIS; URTICARIA; ANALOGS AND DERIVATIVES; DRUG ADMINISTRATION; PRESCHOOL CHILD; SKIN TEST; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

ADOLESCENT; ANTIBIOTICS, ANTITUBERCULAR; ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; ISONIAZID; MALE; MEDICATION ADHERENCE; RIFAMPIN; SKIN TESTS; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84963960009     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000001164     Document Type: Article

References (10)

1. Taylor EM, Painter J, Posey DL, et al. Latent tuberculosis infection among immigrant and refugee children arriving in the United States: 2010. J Immigr Minor Health. [published online ahead of print September 12, 2015]. doi: 10.1007/s10903-015-0273-2.
2. Hirsch-Moverman Y, Shrestha-Kuwahara R, Bethel J, et al.; Tuberculosis Epidemiologic Studies Consortium (TBESC). Latent tuberculous infection in the United States and Canada: who completes treatment and why?. Int J Tuberc Lung Dis. 2015;19:31-38.
3. Cruz AT, Starke JR. Increasing adherence for latent tuberculosis infection therapy with health department-Administered therapy. Pediatr Infect Dis J. 2012;31:193-195.
4. Sterling TR, Villarino ME, Borisov AS, et al.; TB Trials Consortium PREVENT TB Study Team. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365:2155-2166.
5. Villarino ME, Scott NA, Weis SE, et al.; International Maternal Pediatric and Adolescents AIDS Clinical Trials Group; Tuberculosis Trials Consortium. Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. JAMA Pediatr. 2015;169:247-255.
6. American Thoracic Society, the Centers for Disease Control and Prevention, and the Council of the Infectious Diseases Society of America. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000;161:S221-S247.
7. Mazurek GH, Jereb J, Vernon A, et al.; IGRA Expert Committee; Centers for Disease Control and Prevention (CDC). Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection-United States, 2010. MMWR Recomm Rep. 2010;59(RR-5):1-25.
8. Cruz AT, Starke JR. Safety and completion of a 4-month course of rifampicin for latent tuberculous infection in children. Int J Tuberc Lung Dis. 2014;18:1057-1061.
9. Bliven-Sizemore EE, Sterling TR, Shang N, et al.; TB Trials Consortium. Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI. Int J Tuberc Lung Dis. 2015;19:1039-44, i.
10. Sterling TR, Moro RN, Borisov AS, et al.; Tuberculosis Trials Consortium. Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study. Clin Infect Dis. 2015;61:527-535.